Common brand names:
Histrelin is used in men to treat advanced prostate cancer. It is not a cure. Most types of prostate cancer need the male hormone testosterone to grow and spread. Histrelin works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells and helps relieve symptoms such as painful/difficult urination. Talk to your doctor about the risks and benefits of treatment.
Histrelin is also used in children to treat early puberty (central precocious puberty). It helps to slow abnormally fast bone development so that height and growth rate are near normal and to stop or reverse signs of early puberty (such as breast/pubic hair growth in girls, pubic hair growth in boys). Histrelin works by reducing the amount of testosterone in boys and estrogen in girls. This medication is used until the doctor decides it is time for puberty to resume.
How to Use This Medication
Read the Patient Information Leaflet that comes with the histrelin implant. If you have any questions, consult your doctor.
Your doctor will surgically place the medicated implant under the skin of your upper arm. The implant releases histrelin into your blood slowly and continuously over 12 months. After 12 months, your doctor will remove the implant and replace it with a new one. Consult your doctor for details.
It is very important to keep the bandage in place for several days until the surgical incision heals. Keep the incision clean and dry. Avoid bathing and swimming for 24 hours after the procedure. Also avoid any heavy lifting, bumping of the incision site, or physical activity for 7 days after the procedure.
When you first start this medication, new or worsening symptoms may occur. This is a normal response by your body to this drug. Such symptoms should get better after the first month of treatment. Girls being treated for early puberty may notice vaginal bleeding or an increase in breast size or pubic hair. Boys being treated for early puberty may notice an increase in pubic hair. Tell the doctor if the symptoms persist or worsen after 1 month.
New or worsening symptoms may also occur at the beginning of treatment for prostate cancer. Tell your doctor immediately if you experience any of the following serious side effects: bone pain, numbness/tingling/weakness of the arms/legs, blood in the urine, painful/difficult urination, unusual weakness, inability to move. If you have prostate cancer that has spread to the spine or caused problems urinating due to blockage, you may require closer monitoring by your doctor, especially when you first start treatment.
Copyright © 2016 Healthnotes, Inc. All rights reserved. www.healthnotes.com
RxAnswers™ is a copyrighted combined product from Healthnotes and First DataBank, Inc.
Drug information is selected from data included with permission and copyrighted by First DataBank, Inc. This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional. Always seek the advice of your healthcare professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your healthcare professional. This information does not contain any assurances that this product is safe, effective or appropriate for you.
This information is intended only for residents of the United States. Products sold under the same brand names in other countries may contain different ingredients.
There are some limitations on the information provided in “Nutrient Interactions.” Do NOT rely solely on the information in this article. Please read the disclaimer.
Healthnotes and/or its suppliers make no warranties or representations as to the accuracy or completeness of this content herein or that of any organization referred or linked to within this content and will not be liable for any damages arising out of your access to or use of any information found herein or that of any organization referred to within this content.
Information expires June 2016.